Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Among authors: dillon jf. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Minocycline hepatitis.
Ford TJ, Dillon JF. Ford TJ, et al. Among authors: dillon jf. Eur J Gastroenterol Hepatol. 2008 Aug;20(8):796-9. doi: 10.1097/MEG.0b013e3282f493c5. Eur J Gastroenterol Hepatol. 2008. PMID: 18617786
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ. McDonald SA, et al. Among authors: dillon jf. J Hepatol. 2015 Feb;62(2):262-8. doi: 10.1016/j.jhep.2014.08.046. Epub 2014 Sep 6. J Hepatol. 2015. PMID: 25195556
The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort.
Wang H, Innes H, Hutchinson SJ, Goldberg DJ, Allen S, Barclay ST, Bramley P, Fox R, Fraser A, Hayes PC, Kennedy N, Mills PR, Dillon JF. Wang H, et al. Among authors: dillon jf. Eur J Gastroenterol Hepatol. 2016 Apr;28(4):398-404. doi: 10.1097/MEG.0000000000000556. Eur J Gastroenterol Hepatol. 2016. PMID: 26695428
Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Innes H, et al. Among authors: dillon jf. J Hepatol. 2017 Jan;66(1):19-27. doi: 10.1016/j.jhep.2016.08.004. Epub 2016 Aug 18. J Hepatol. 2017. PMID: 27545496
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M, Roberts T, Crooks L, Midgard H, Larney S, Degenhardt L, Alho H, Byrne J, Dillon JF, Feld JJ, Foster G, Goldberg D, Lloyd AR, Reimer J, Robaeys G, Torrens M, Wright N, Maremmani I, Norton BL, Litwin AH, Dore GJ; International Network on Hepatitis in Substance Users. Grebely J, et al. Among authors: dillon jf. Int J Drug Policy. 2017 Sep;47:51-60. doi: 10.1016/j.drugpo.2017.05.019. Epub 2017 Jul 3. Int J Drug Policy. 2017. PMID: 28683982 Free PMC article.
239 results